Merck & Co., Inc. is 129.6x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($293.16 B vs $2.26 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RARE | MRK |
|---|---|---|
| Market cap | $2.26 B | $293.16 B |
| US-listed rank | #2014 | #44 |
| Revenue (latest FY) | $673.00M | $65.01B |
| Net income (latest FY) | -$575.00M | $18.25B |
| Net margin | -85.4% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 1,100 | 996 |
Merck & Co., Inc. is 129.6x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($293.16 B vs $2.26 B).
In their latest fiscal years, Ultragenyx Pharmaceutical Inc. reported $673.00M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Ultragenyx Pharmaceutical Inc. and Merck & Co., Inc., or browse the full rankings.